Last reviewed · How we verify

albiglutide + insulin glargine

GlaxoSmithKline · Phase 3 active Biologic

albiglutide + insulin glargine is a GLP-1 receptor agonist and long-acting basal insulin analog Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Type 2 diabetes mellitus, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day.

Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day. Used for Type 2 diabetes mellitus, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

At a glance

Generic namealbiglutide + insulin glargine
SponsorGlaxoSmithKline
Drug classGLP-1 receptor agonist and long-acting basal insulin analog
TargetGLP-1R
ModalityBiologic
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Albiglutide works by binding to GLP-1 receptors in the pancreas, stimulating insulin release in response to elevated glucose levels. Insulin glargine, on the other hand, is a modified form of human insulin that is designed to be released slowly and steadily over a 24-hour period, providing a basal level of insulin to help control blood sugar levels.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about albiglutide + insulin glargine

What is albiglutide + insulin glargine?

albiglutide + insulin glargine is a GLP-1 receptor agonist and long-acting basal insulin analog drug developed by GlaxoSmithKline, indicated for Type 2 diabetes mellitus, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

How does albiglutide + insulin glargine work?

Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day.

What is albiglutide + insulin glargine used for?

albiglutide + insulin glargine is indicated for Type 2 diabetes mellitus, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Who makes albiglutide + insulin glargine?

albiglutide + insulin glargine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is albiglutide + insulin glargine in?

albiglutide + insulin glargine belongs to the GLP-1 receptor agonist and long-acting basal insulin analog class. See all GLP-1 receptor agonist and long-acting basal insulin analog drugs at /class/glp-1-receptor-agonist-and-long-acting-basal-insulin-analog.

What development phase is albiglutide + insulin glargine in?

albiglutide + insulin glargine is in Phase 3.

What are the side effects of albiglutide + insulin glargine?

Common side effects of albiglutide + insulin glargine include Nausea, Injection site reactions, Diarrhea, Abdominal pain, Headache, Fatigue.

What does albiglutide + insulin glargine target?

albiglutide + insulin glargine targets GLP-1R and is a GLP-1 receptor agonist and long-acting basal insulin analog.

Related